Inactivation of Influenza and Vesicular Stomatitis Virion RNA ...
Immunogenicity and safety after one dose of adjuvanted …...1 Immunogenicity and safety after one...
Transcript of Immunogenicity and safety after one dose of adjuvanted …...1 Immunogenicity and safety after one...
-
Elsevier Editorial System(tm) for The Lancet Manuscript Draft Manuscript Number: Title: Immunogenicity and safety after one dose of adjuvanted whole-virion, adjuvanted split-virion and non-adjuvanted split-virion influenza A (H1N1)vaccines: a double-blind, randomized and controlled trial Article Type: Article (Randomised Controlled Trial) Corresponding Author: Mr. Weidong Yin, MBA Corresponding Author's Institution: Sinovac Biotech Co., Ltd First Author: Jiang Wu, MSc Order of Authors: Jiang Wu, MSc ; Wei Li, MSc; Hua-Qing Wang, Msc; Jiang-Ting Chen, BSc; Min Lu, PhD; Ji-Chen Zhou, BSc; Xiao-Feng Liang, MSc; Han-Hua Fang, BSc; Yan Liu, MSc; Li-Ying Liu, BSc; Xu Wang, BSc; Wu-Li Zhang, BSc; Xiao-Mei Zhang, BSc; Li-Fei Song, MSc; Yuan-Zheng Qiu, PhD; Chang-Gui Li, MSc; Jun-Zhi Wang, PhD; Yu Wang, PhD; Weidong Yin, MBA Abstract: Background A novel swine-origin influenza A (H1N1) virus had caused a pandemic influenza. The vaccines against the virus is undergoing clinical evaluation in many countries. Herein we report the results of immunogenicity and safety after one dose of adjuvanted whole-virion, adjuvanted split-virion and non-adjuvanted split-virion influenza A (H1N1) vaccines. Methods A double-blind, randomized and controlled trial was conducted in 1614 participants including 101 elders (≥61 years), 706 adults (18-60 years), 403 adolescents (12-17 years) and 404 children (3-11 years). The elders were assigned to receive 1 dose of 10-μg, adjuvanted whole-virion vaccine. The adults, adolescents and children were randomly assigned to receive 2 doses of the study vaccines 21 days apart. The adults received 5-30 μg of the three formulations of the study vaccines or placebo. The adolescents and children received 7*5-30 μg of adjuvanted or non-adjuvanted split-virion vaccines. Blood samples were collected for haemagglutination-inhibition (HI) assay. Adverse events were recorded after vaccination. The trial is registered with the ClinicalTrials.gov number NCT00956111. Findings All formulations were well tolerated with no serious adverse events. Most local and systemic reactions were mild or moderate. Before vaccination, some degree of preexisting immunity was found in participants more than 12 years. One dose of all the three formulations of the study vaccines induced satisfactory HI response complying with the licensure criteria set out by European Union in participants aged 3-60 years. The dose-dependent relationship was generally found. The highest immune response was observed in adults, adolescents and children after one dose of 30-μg non-adjuvanted split-virion vaccine with HI geometric mean titer (GMT) of 113-601, seroconversion rate of 95-98% and seroprotection rate of 96-100%. An unexpected finding was that aluminium adjuvant did not boost the immune response. One dose of 15-μg non-adjuvanted split-virion vaccine induced immune response with HI GMT of 79-475, seroconversion rate of 81-98% and seroprotection rate of 81-98% in adults, adolescents and children, which was better than that induced by 15-μg adjuvanted split-virion vaccine. Interpretation All the investigated three formulations of influenza A (H1N1) vaccine were well tolerated and immunogenic. One dose vaccination could induce satisfactory immune response in population aged 3-60 years. In the view of antigen sparing, the 15-μg non-adjuvanted split-virion vaccine is applicable for mass immunization.
-
1
Immunogenicity and safety after one dose of adjuvanted whole-virion,
adjuvanted split-virion and non-adjuvanted split-virion influenza A
(H1N1)vaccines: a double-blind, randomized and controled trial
Jiang Wu1, Wei Li
2, Hua-Qing Wang
3, Jiang-Ting Chen
4, Min Lu
1, Ji-Chen Zhou
5, Xiao-Feng Liang
3,
Han-Hua Fang2, Yan Liu
4, Li-Ying Liu
5, Xu Wang
4, Wu-Li Zhang
5, Xiao-Mei Zhang
4, Li-Fei Song
4,
Yuan-Zheng Qiu4, Chang-Gui Li
2, Jun-Zhi Wang
2, Yu Wang
3, Wei-Dong Yin
4†
1 Beijing Centers for Disease Control and Prevention, Beijing, China
2 National Institute for the Control of Pharmaceuticals and Biological Products, Beijing, China
3 Chinese Centers for Disease Control and Prevention
4 Sinovac Biotech Co. Ltd, Beijing, China
5 Huairou Center for Disease Control and Prevention, Beijing, China
† Corresponding authors:
Wei-Dong Yin
Tel: +86-10-82890878 Fax: +86-10-62966910 Email: [email protected]
Manuscript
-
2
Summary
Background A novel swine-origin influenza A (H1N1) virus had caused a pandemic influenza. The
vaccines against the virus is undergoing clinical evaluation in many countries. Herein we report the results
of immunogenicity and safety after one dose of adjuvanted whole-virion, adjuvanted split-virion and
non-adjuvanted split-virion influenza A (H1N1) vaccines.
Methods A double-blind, randomized and controled trial was conducted in 1614 participants including
101 elders (≥61 years), 706 adults (18–60 years), 403 adolescents (12–17 years) and 404 children (3–11
years). The elders were assigned to receive 1 dose of 10-μg, adjuvanted whole-virion vaccine. The adults,
adolescents and children were randomly assigned to receive 2 doses of the study vaccines 21 days apart.
The adults received 5–30 μg of the three formulations of the study vaccines or placebo. The adolescents
and children received 7·5–30 μg of adjuvanted or non-adjuvanted split-virion vaccines. Blood samples
were collected for hemagglutination-inhibition (HI) assay. Adverse events were recorded after vaccination.
The trial is registered with the ClinicalTrials.gov number NCT00956111.
Findings All formulations were well tolerated with no serious adverse events. Most local and systemic
reactions were mild or moderate. Before vaccination, some degree of preexisting immunity was found in
participants more than 12 years. One dose of all the three formulations of the study vaccines induced
satisfactory HI response complying with the licensure criteria set out by European Union in participants
aged 3–60 years. The dose-dependent relationship was generally found. The highest immune response was
observed in adults, adolescents and children after one dose of 30-μg non-adjuvanted split-virion vaccine
with HI geometric mean titer (GMT) of 113–601, seroconversion rate of 95–98% and seroprotection rate
of 96–100%. An unexpected finding was that aluminum adjuvant did not boost the immune response. One
dose of 15-μg non-adjuvanted split-virion vaccine induced immune response with HI GMT of 79–475,
seroconversion rate of 81–98% and seroprotection rate of 81–98% in adults, adolescents and children,
which was better than that induced by 15-μg adjuvanted split-virion vaccine.
Interpretation All the investigated three formulations of influenza A (H1N1) vaccine were well
-
3
tolerated and immunogenic. One dose vaccination could induce satisfactory immune response in
population aged 3–60 years. In the view of antigen sparing, the 15-μg non-adjuvanted split-virion vaccine
is applicable for mass immunization.
(Summary word count: 382)
-
4
Introduction
A novel swine-origin influenza A (H1N1) virus emerging in North America had caused a pandemic
influenza as declared by the World Health Organization (WHO) on June 11, 2009.1 As of August 13, 2009,
more than 170 countries and regions worldwide reported over 180,000 cases, 1799 of which were fatal.2
The rapid spread of the virus and high morbidity caused by it has drawn wide attention from international
community. So far vaccine is considered as the most effective means to reduce the morbidity and mortality
after infection, especial for those who have underlying medical conditions.
Up to now, clinical evaluation of influenza A (H1N1) vaccine is ongoing in China, Australia, USA, Austria
and European Union.3 None of these trials has been completed. As registered in ClinicalTrials.gov, the
vaccines to be evaluated included whole-virion and split-virion vaccines, adjuvanted and non-adjuvanted
vaccines, egg-derived and cell-derived vaccines, all of which were monovalent vaccine. The dosage of the
investigated vaccines ranged from 3·75 μg to 30 μg, depending on the adjuvant and vaccine type. The
study population covered infants, children, adolescents, adults and elders. Two-dose vaccination schedule
was adopted by all these trials, most of which were 21-day interval. Based on the experience with H5N1
vaccine trials which showed that two doses were necessary to induce satisfactory immune response in
immunologically naïve population, 4–7
it is little expected that one dose could elicit satisfactory immune
response.
To evaluate the immunogenicity and safety of influenza A (H1N1) vaccines manufactured by Sinovac
Biotech (Beijing, China), a double-blind, randomized and controled trial was conducted in elders, adults,
adolescents and children. The study design is two-dose vaccination and participants will be followed up
for at least 42 days. After participants received one dose and completed the visit of day 21, however, as
required by Chinese Centers for Disease Control and Prevention (CDC) and reviewed by Data Security
Monitor Board and experts committee, the investigators and sponsor decided to do code-breaking in order
to have preliminary evaluation of the investigated vaccines. Herein we reported the results after one dose
of the study vaccines. The results after two doses will be presented in additional report when the entire
trial is completed.
-
5
Methods
Participants
From July 15 to 25, 2009, a total of 1614 participants were enrolled from healthy male or non-pregnant
female volunteers aged 3-75 years in Huairou District, Beijing, China. Eligible participants were clinically
healthy as determined by history talking and physical examination. The main exclusion criteria were:
current febrile illness as determined by over 37·0℃ axillary temperature on the day of vaccination; cases or
cured cases of influenza A (H1N1) virus or those close contacting with cases; any acute diseases; allergic
history to vaccines and eggs; history of hematologic, hepatic, renal, cardiac or respiratory diseases;
immunodeficiency; treatment with cytotoxic or immunosuppressive drugs within the past 6 months;
receipt of blood, blood-derived products or any other vaccines within the past 3 months; currently attended
or planed to attend any other clinical trials; unable to comply with the visit schedule. Woman volunteers
who were of pregnancy or lactation or planned to be pregnant in 60 days were excluded.
The trial was registered with the ClinicalTrials.gov number NCT00956111 and approved by the Chinese
regulatory authority State Food and Drug Administration (SFDA) and Chinese CDC. All relevant
documents were approved by the ethical review committee of Beijing Centers for Disease Control and
Prevention. All participants gave their written informed consent.
Procedures
The vaccine strain X-179A was used in this study for vaccine production which was a reassortant between
A/California/07/2009 and A/PR/8/34 prepared by New York Medical College using classical reassortment
technology. The strain was recommended by WHO for the development of influenza A (H1N1) vaccine.8
The vaccines used in this study were produced by Sinovac Biotech (Beijing, China) on a pilot scale in
embryonated hens’ eggs as previously reported.6 Three formulations of influenza A (H1N1) vaccine were
used: aluminum-adjuvanted whole-virion vaccine, aluminmium-adjuvanted split-virion vaccine and
non-adjuvanted split-virion vaccine, which were prepared in vial as 20 μg/mL/vial (lot W-20090702), 30
μg/mL/vial (lot S-20090702) and 60 μg/mL/vial (lot 20090704), respectively. Each vial contained 2 or 4
doses. The two adjuvanted vaccines were formulated with aluminum hydroxide to contain aluminum of
-
6
0·3–0·6 mg/mL. The placebo control was phosphate buffer saline (lot E-R090630-110). All vaccines and
placebo were free of preservative. The vaccines or placebo were given at two-dose schedule (day 0, 21) or
one-dose schedule. The vaccines or placebo given at two-dose schedule (for adults, adolescents and
children) were subjected to stratification and randomization. A randomization list was generated by a
statistician who was not involved in the rest of the trial. Then the randomized vaccines were blindly
labeled with a sequential number according to the randomization list. The vaccines given at one-dose
schedule (for elders) were openly labelled. The vaccines were stored and transported at 2℃ to 8℃.
The trial profile is shown in Figure 1. The eligible participants were stratified by age: elders (≥61 years),
adults (18–60 years), adolescent (12–17 years) and children (3–11 years). The elders were assigned to
receive one dose of openly-labelled, 10-μg, adjuvanted whole-virion vaccine. The adults, adolescents and
children were randomly assigned to receive two doses of blind-labelled vaccines or placebo 21 days apart.
The adults received 2 doses of 5 or 10 μg of adjuvanted, whole-virion vaccine, or 7·5 or 15 μg of
adjuvanted, split-virion vaccine, or 15 or 30 μg of non-adjuvanted, split-virion vaccine, or placebo. The
adolescents and children received 2 doses of 7·5 or 15 μg of adjuvanted, split-virion vaccine, or 15 or 30
μg of non-adjuvanted, split-virion vaccine. Participants received either 0·5 or 0·25 mL per dose, depending
on the random allocation. The vaccines were administered intramuscularly into the deltoid muscle by a
nurse who did not participated in the safety observation and immunogenic assessment.
Participants were kept to observe adverse events for 30 minutes after vaccination. Diary cards were used
to record the presence and intensity of adverse events. In the next three days following vaccination, any
local adverse events (pain, erythema, swelling, induration, rash and itching) at the injection site and
systemic adverse events (allergic reactions, headache, dizziness, fatigue, angina, nausea, vomit,
inappetence, abdominal pain, diarrhea, myalgia, arthralgia, cough, fever) would be recorded on the diary
cards. The diameters of any erythema, swelling, induration and rash were determined by investigators, and
the daily axillary temperatures were measured by volunteers themselves. The adverse events recorded by
participants were reviewed by investigators. All adverse events were graded by a standard scale.9,10
Serum samples for the assessment of humoral immune response were collected on day 0, 14, 21 and 35 for
elders, on day 0, 14, 21, 35 and 42 for adults and adolescents, on day 0, 21 and 42 for children. All serum
samples were assayed by hemagglutination-inhibition (HI) methods against the homologous X-179A strain.
-
7
The immunogenic assays were blindly performed. HI assays were done in accordance with established
procedures using turkey erythrocytes as reported previously.6
Briefly, serum samples were treated with
receptor-destroying enzyme (cholera filtrate, Sigma) at 36℃ for 16 h before titration in order to remove
non-specific inhibitors of agglutination. Samples were tested in two-fold dilution starting with 1:10
dilution. The titers were expressed as the reciprocal of the highest dilution that showed complete inhibition
of haemagglutination. All samples were assayed in duplicate and double-checked by at least two persons.
For the purpose of calculation, HI titers below 1:10 were assigned a value of 1:5.
Statistical analysis
Safety and immunogenicity were the co-primary objectives. The incidence of adverse events was based on
the most severe response, expressed in terms of the number and proportion of individuals who had adverse
events. The safety data were summarized in the full-analysis set.
The immunologic endpoints were based on HI licensure criteria set out by the European Union Committee
for Medicinal Products for Human Use (CHMP) including geometric mean titer (GMT),
post-to-pre-vaccination GMT ratio, seroconversion rate and seroprotection rate.11,12
Seroconversion rate is
defined as the percentage of vaccinees who have a titer before vaccination of less than 1:10 and a titer after
vaccination of 1:40 or more, or a titer before vaccination of 1:10 or more and at least a fourfold increase
after vaccination. HI titer≥1:40 is considered as seroprotection in seasonal influenza vaccine, which is
temporally adopted for influenza A (H1N1) vaccine in this study. The antibody titers were transformed
into logarithmic scale for the calculation of GMT. The titer distributions were described with reverse
cumulative distribution curves. The immunogenic data were summarized in the per-protocol set.
The results of immunogenicity and safety were summarized with point estimates and two-sided 95%CI.
Pearson’s chi-square test or Fisher’s exact test were used to compare groups when relevant. The statistical
analysis was conducted by an independent statistician. Statistical analysis was done by intension to
treatment. The significance level was 0·05 (two-sided).
Role of the funding source
This study was funded by a research grant from Sinovac Biotech which had a role in study design, trial
monitoring, interpretation of data and writing of the report. The sponsor had no role in data collection. The
corresponding authors had full access to all the data and had final responsibility for the decision to submit
-
8
for publication.
Results
A total of 1614 participants were enrolled and stratified by age including 101 elders, 706 adults, 403
adolescents and 404 children. The adults were randomly allocated into 7 groups with 100–102 per group.
The adolescents were randomly allocated into 4 groups with 100–102 per group. The children were
randomly allocated into 4 groups with 100–102 per group. All participants received the first dose and
completed the safety observation, and one elder was excluded by investigator due to protocol violation.
Then 1613 participants were included in safety analysis. Eight and 31 participants dropped out on day 14
and 21, respectively. Then 1613, 1201 (404 children not attended the visit) and 1582 participants were
included in immunogenicity analysis on day 0, 14 and 21, respectively. The demographic details of the
study population are summarized in Table 1 and 2. In term of age and sex, statistical differences were not
found in the vaccination groups of adults (P=0·964 and P=0·837), of adolescents (P=0·904 and P=0·438),
of children (P=0·479 and P=1·000).
All vaccine formulations were well tolerated without immediate allergic reactions or serious adverse
events. The adverse reactions are shown in Table 3 and 4. A total of 189 participants (incidence of 11·7%)
reported adverse reactions, and the incidences of mild, moderate and severe reactions were 9·1%, 2·5%
and 0·1%, respectively. Pain (5·1%) at the injection site was the most common local reaction. The main
systemic reactions were myalgia (1·9%), headache (1·7%), fatigue (1·7%) and fever (1·6%). In adults, the
incidence of adverse reactions in participants receiving placebo was statistically similar to that in
participants receiving the study vaccines (7% vs 13·2%, P=0·08). The incidences of adverse reactions were
not statistically different in the 6 groups of adults receiving the study vaccines (P=0·249), in the 4 groups
of adolescents (P=0·991), and in the 4 groups of children (P=0·262).
The results of HI assays are summarized in Table 5, 6 and Figure 2. Before vaccination, 80 out of 1613
participants (5·0%) included in immunogenic analysis showed seroprotective antibody (HI≥1:40). The
pre-vaccination seroprotection rate in the 4 age strata ranged from 0·2% to 10·2% with the adolescents
having the highest and the children having the lowest. After receiving one dose of the study vaccines, HI
antibody responses were significantly induced in adults, adolescents and children. The GMTs, GMT ratios,
-
9
seroconversion rates and seroprotection rates in the 3 age strata were 44–601, 8–66, 64–98% and
64–100% on day 21, respectively. However, the immune response was lower in elders where the GMT,
GMT ratio, seroconvertion rate and seroprotection rate were 41, 5, 50% and 56% on day 14, respectively.
The dose-dependent relationship was generally found in the three formulations of the study vaccines. The
highest immune response was observed in adults, adolescents and children after one dose of 30-μg
non-adjuvanted split-virion vaccine with HI GMT of 113–601, seroconversion rate of 95–98% and
seroprotection rate of 96–100%. One dose of 15-μg non-adjuvanted split-virion vaccine also induced high
immune response with HI GMT of 79–475, seroconversion rate of 81–98% and seroprotection rate of
81–98% in adults, adolescents and children, which was better than that induced by 15-μg adjuvanted
split-virion vaccine (P
-
10
might be applicable.
An unexpected finding of this trial is that influenza A (H1N1) vaccine is of good immunogenicity. Except
for in elders (≥61 years), one dose of the investigated influenza A (H1N1) vaccines induced satisfactory
immune response complying with all the three licensure criteria (GMT ratio, seroconversion rate and
seroprotection rate) set out by EU CHMP in population aged 3-60 years. The immune response induced by
influenza A (H1N1) vaccine is similar to that of seasonal influenza vaccine. In adults, all the three
formulations (each containing two dosages) induced immune response meeting the three criteria 14 and 21
days after one dose. In adolescents, all the two formulations (each containing two dosages) induced
immune response meeting the three criteria 14 and 21 days after one dose. In children, except for 7.5-μg
adjuvanted split-virion vaccine, the 15-μg adjuvanted split-virion vaccine and 15- and 30-μg
non-adjuvanted split-virion vaccine induced immune response meeting the three criteria 21 days after one
dose. In elders, although the seroprotection rate after one dose of 10-μg adjuvanted whole-virion vaccine
did not comply with the EU CHMP criteria, it is very close to it.
Another unexpected finding is that aluminum adjuvant dose not boost the immune response. However, the
aluminum-adjuvanted vaccines elicited lower immune response than its non-adjuvanted counterparts did,
which was found in children, adolescents and adults. This phenomena was also found in previous trial with
H5N1 vaccine.5 In view of the sustained release endowed by adjuvant, a longer term may be needed to
observe the effect of adjuvant on immune response. At the current stage, it is too early to draw a
conclusion about the adjuvant effect.
Before vaccination, some degree of preexisting immunity against the novel influenza A (H1N1) virus was
found in the study population more than 12 years, which agreed with our previous study.14
The satisfactory
immune response after one dose vaccination may largely attribute to the preexisting immunity. In children
aged 3–11 years, the immune response after one dose was lower than that in adolescents and adults, which
may largely attribute to the absence of preexisting immunity. Although preexisting immunity was found in
elders, the immune response in elders did not comply with the licensure criteria after one dose, which was
probable due to the effect of age on immune response. Then the preexisting immunity and age would be
the two critical factors affecting the immune response after vaccination.
The safety data showed that the three formulations of the study vaccines were well tolerated without
-
11
serious adverse reactions. Most of the adverse reactions were mild or moderate. The profile of adverse
reactions was similar to that of seasonal influenza vaccines. Although the incidence of adverse reactions in
participants receiving vaccines was slightly higher than that in participants receiving placebo, the
difference was not statistically significant.
Based on the immunogenicity and safety results in this study and the considerations for antigen sparing
and production capacity, we can conclude that 15-μg non-adjuvanted split-virion vaccine is applicable for
the immunization of population aged 3–60 years. For adults aged 18–60 years, 5-μg adjuvanted
whole-virion vaccine and 7.5-μg adjuvanted split-virion vaccine are also applicable. For adolescents,
7.5-μg adjuvanted split-virion vaccine is also applicable. What formulation and dosage is applicable for
the immunization in elders needs further study.
In conclusion, this study found that all the investigated three formulations of influenza A (H1N1) vaccine
were well tolerated and immunogenic. One dose vaccination could induce satisfactory immune response in
population aged 3–60 years. In the view of antigen sparing, the 15-μg non-adjuvanted split-virion vaccine
is applicable for mass immunization. These results in this study would be helpful for the ongoing clinical
trials of influenza A (H1N1) vaccines produced by other manufacturers and it also provided public health
authorities with the feasibility to deploy vaccine ahead of the planned schedule in order to control
influenza A (H1N1) as earlier as possible.
(Summary word count: 2955)
Contributors
All authors played their roles in the study. J Wu was the principal investigator leading the clinical team
assisted by M Lu, JC Zhou, LY Liu and WL Zhang. J Wu, JT Chen, WD Yin, HQ Wang, XF Liang and Y
Wang jointly designed the protocol with expert advice. XM Zhang was responsible for the production of
the study vaccine. X Wang and YZ Qiu were responsible for trial monitoring. M Lu and Y Liu did the data
analysis. HH Fang, CG Li, JZ Wang, W Li and LF Song were responsible for the laboratory assay.
Conflict of interest statement
WD Yin, XM Zhang, JT Chen, Y Liu, X Wang, YZ Qiu and LF Song are employed by Sinovac Biotech. J
Wu had ever received research funding from Sinovac Biotech. All other authors declare no conflict of
-
12
interest.
Acknowledgments
We appreciate the US Centers for Disease Control and Prevention and the UK National Institute for
Biological Standards and Control for the kindly providing the vaccine strains and reference standards. We
also thank YD Zheng from Peking University Health Science Center for the help of statistical analysis, X
Zhong and YD Zhou from Sinova Biotech for the help of manuscript writing.
References
1. World Health Organization. DG Statement following the meeting of the Emergency Committee.
http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html (accessed August 5, 2009)
2. World Health Organization. Laboratory-confirmed cases of pandemic (H1N1) 2009 as officially
reported to WHO by States Parties to the IHR (2005) as of 13 August 2009.
http://www.who.int/csr/don/2009_08_19/en/index.htmlon (accessed August 20, 2009)
3. ClinicalTrials.gov. H1N1 vaccine trial. http://clinicaltrials.gov/ct2/results?term= H1N1+vaccine+trial
(accessed August 20, 2009)
4. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an
inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343–51.
5. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion
influenza A/Vietnam/1194/2004 (H5N1) Vaccine: phaseⅠrandomized trial. Lancet 2006; 367: 1657–64.
6. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion
influenza A (H5N1) vaccine: a phase I randomised controled trial. Lancet 2006; 368: 991–97.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity
with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controled trial. Lancet
2007; 370: 580–89.
8. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel
influenza A (H1N1) vaccine development X-179A.
http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/ (accessed August 20,
http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/%20en/index.html
-
13
2009)
9. Division of Microbiology and Infectious Diseases. Adult toxicity table.
http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/toxtables.htm (accessed
August 20, 2009)
10. Division of Microbiology and Infectious Diseases. Pediatric toxicity table.
http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/toxtables.htm (accessed
August 20, 2009)
11. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of
requirements for influenza vaccines (CPMP/BWP/214/96). European Agency for the Evaluation of
Medicinal Products, 1997.
12. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content
for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European
Agency for the Evaluation of Medicinal Products, 2004.
13. Katz J, Hancock K, Veguilla V, et al. Serum Cross-Reactive Antibody Response to a Novel Inluenza A
(H1N1) Virus After Vaccination with Seasonal Influenza Vaccine. MMWR 2009;58: 521-4.
14. Fang HH, Wu J, Zhang ZL, Jiang FC, Chen JT. Preexisting immunity and cross-reactive immunity to
a novel influenza A (H1N1) virus in Chinese population. Lancet 2009 (submitted)
-
14
Table 1 Demographic characteristics of the study population by age
Elders
(n=100)
Adults
(n=706)
Adolescents
(n= 403)
Children
(n=404)
Total
(n=1613)
Age (y)
Mean±SD 66·4±4·2 41·6±10·0 14·3±1·5 7·3±2·6 27·7±19·3
Median(range) 65·0
(61–75)
43·0
(18–60)
14·0
(12–17)
8·0
(3–11)
17·5
(3–75)
Male/Female 1·30 0·69 0·88 1·00 0·84
-
15
Table 2 Demographic characteristics of the study population by vaccine type and dose
Vaccine type and dose
Adjuvanted whole–virion
Adjuvanted split–virion
Non–adjuvanted
split–virion
Placebo
(n=100) 5 μg
(n=101)
10 μg
(n=102)
7·5 μg
(n=101)
15 μg
(n=100)
15 μg
(n= 101)
30 μg
(n= 101)
Adults
Age (y)
Mean±SD 41·3±10·0 41·1±9·9 41·1±10·2 41·7±10·1 41·6±10·3 41·9±9·6 42·0±9·8
Median (range) 42·0
(18–60)
42·0
(18–60)
42·0
(18–59)
43·0
(18–59)
42·0
(18–60)
43·0
(19–60)
44·0
(18–60)
Male/Female 0·74 0·65 0·58 0·69 0·63 0·71 0·89
Adolescents
Age (y) / / /
Mean±SD / / 14·3±1·7 14·4±1·6 14·3±1·5 14·3±1·5 /
Median (range) / /
14·0
(12–17)
14·0
(12–17)
14·0
(12–17)
14·0
(12–17) /
Male/Female / / 1·04 0·85 0·68 1·00 /
Children
Age (y) / / /
Mean±SD / / 7·7±2·3 7·3±2·6 7·1±2·6 7·2±2·8 /
Median (range) / /
8·0
(3–11)
8·0
(3–11)
7·0
(3–11)
8·0
(3–11) /
Male/Female / / 1·08 0·85 0·96 1·13 /
-
16
Table 3 Participants with adverse reactions after one dose by age
Elders (n=100) Adults (n=706 )
Adolescents
(n= 403) Children (n=404 ) Total (n=1613)
Total 1·0 (1) 12·3 (87) 10·7 (43) 14·4 (58) 11·7 (189)
Mild 1·0 (1) 10·1 (71) 9·4 (38) 9·2 (37) 9·1 (147)
Moderate 0·0 (0) 2·1 (15) 1·0 (4) 5·2 (21) 2·5 (40)
Severe 0·0 (0) 0·1 (1) 0·2 (1) 0·0 (0) 0·1 (2)
Local reactions 0·0 (0) 6·4 (45) 5·0 (20) 5·9 (24) 5·5 (89)
Pain 0·0 (0) 5·9 (42) 4·7 (19) 5·4 (22) 5·1 (83)
Erythema 0·0 (0) 0·0 (0) 0·0 (0) 0·2 (1) 0·1 (1)
Swelling 0·0 (0) 0·0 (0) 0·0 (0) 0·2 (1) 0·1 (1)
Induration 0·0 (0) 0·4 (3) 0·0 (0) 0·0 (0) 0·2 (3)
Itching 0·0 (0) 0·3 (2) 1·0 (4) 1·0 (4) 0·6 (10)
Others 0·0 (0) 0·1 (1) 0·0 (0) 0·0 (0) 0·1 (1)
Systemic reactions 1·0 (1) 7·9 (56) 7·7 (31) 10·9 (44) 8·2 (132)
Fever* 0·0 (0) 0·8 (6) 1·7 (7) 3·2 (13) 1·6 (26)
Allergy 0·0 (0) 0·6 (4) 1·0 (4) 0·7 (3) 0·7 (11)
Headache 0·0 (0) 2·3 (16) 1·7 (7) 1·0 (4) 1·7 (27)
Dizziness 0·0 (0) 1·3 (9) 1·7 (7) 1·7 (7) 1·4 (23)
Fatigue 1·0 (1) 2·1 (15) 1·5 (6) 1·2 (5) 1·7 (27)
Angina 0·0 (0) 0·7 (5) 1·2 (5) 0·2 (1) 0·7 (11)
Nausea 0·0 (0) 0·8 (6) 2·0 (8) 1·0 (4) 1·1 (18)
Vomit 0·0 (0) 0·1 (1) 0·0 (0) 0·0 (0) 0·1 (1)
Inappetence 0·0 (0) 0·3 (2) 0·2 (1) 0·7 (3) 0·4 (6)
Abdominal pain 0·0 (0) 0·6 (4) 1·2 (5) 0·5 (2) 0·7 (11)
Diarrhea 0·0 (0) 0·7 (5) 0·0 (0) 0·5 (2) 0·4 (7)
Myalgia 0·0 (0) 2·4 (17) 1·7 (7) 1·5 (6) 1·9 (30)
Arthralgia 0·0 (0) 0·8 (6) 0·2 (1) 0·2 (1) 0·5 (8)
Cough 0·0 (0) 0·3 (2) 0·5 (2) 1·7 (7) 0·7 (11)
Activity level 0·0 (0) 0·3 (2) 0·2 (1) 0·2 (1) 0·2 (4)
Others 0·0 (0) 0·3 (2) 0·7 (3) 0·0 (0) 0·3 (5)
Data are proportion (number) of participants with adverse reactions
-
17
Table 4 Participants with adverse reactions after one dose by vaccine type and dose
Vaccine type and dose
Adjuvanted
whole-virion
Adjuvanted
split-virion
Non-adjuvanted
split-virion
Placebo
5 μg 10 μg 7·5 μg 15 μg 15 μg 30 μg
Adults
N 101 102 101 100 101 101 100
Total 12·9 (13) 19·6 (20) 14·9 (15) 12·0 (12) 7·9 (8) 11·9 (12) 7·0 (7)
Mild 9·9 (10) 17·8 (18) 12·9(13) 12·0 (12) 5·0 (5) 7·9 (8) 5·0 (5)
Moderate 2·0 (2) 2·0 (2) 2·1(2) 0·0 (0) 3·0 (3) 4·0 (4) 2·0 (2)
Severe 1·0 (1) 0·0 (0) 0·0 (0) 0·0 (0) 0·0 (0) 0·0 (0) 0·0 (0)
Local reactions 6·9 (7) 9·8 (10) 5·9 (6) 7·0 (7) 3·0 (3) 7·9 (8) 4·0 (4) Systemic reactions 9·9 (10) 11·8 (12) 10·9 (11) 6·0 (6) 6·9 (7) 5·9 (6) 4·0 (4)
Adolescents
N / / 100 100 101 102 /
Total / / 11·0 (11) 11·0 (11) 10·9 (11) 9·8 (10) /
Mild / / 9·0 (9) 10·0 (10) 9·9 (10) 8·8 (9) /
Moderate / / 2·0 (2) 1·0 (1) 1·0 (1) 0·0 (0) /
Severe / / 0·0 (0) 0·0 (0) 0·0 (0) 1·0 (1) /
Local reactions / / 7·0 (7) 6·0 (6) 5·0 (5) 2·0 (2) /
Systemic reactions / / 5·0 (5) 8·0 (8) 9·9 (10) 7·8 (8) /
Children
N / / 102 100 100 102 /
Total / / 14·7 (15) 13·0 (13) 10·0(10) 19·6 (20) /
Mild / / 11·8 (12) 9·0 (9) 7·0 (7) 8·8 (9) /
Moderate / / 2·9 (3) 4·0 (4) 3·0 (3) 10·8 (11) /
Severe / / 0·0 (0) 0·0 (0) 0·0 (0) 0·0 (0) /
Local reactions / / 6·9 (7) 8·0 (8) 4·0 (4) 4·9 (5) /
Systemic reactions / / 7·8 (8) 10·0 (10) 7·0 (7) 18·6 (19) /
Data are proportion (number) of participants with adverse reactions
-
18
Table 5 Hemagglutination-inhibition antibody response after one dose in adults and elders
Adults (18–60 y) Elders(≥61 y)
Placebo Whole-virion+Al Split-virion+Al Split-virion Whole-virion+Al
5 μg 10 μg 7·5 μg 15 μg 15 μg 30 μg 10 μg
Before vaccination
N 100 101 102 101 100 101 101 100
GMT 7·0
(6·2–7·8)
6·5
(5·8–7·3)
6·8
(6·1–7·7)
7·0
(6·1–8·1)
6·8
(6·1–7·7)
6·6
(5·8–7·6)
7·4
(6·4–8·6)
8·6
(7·3–10·1)
Seroprotection (%)
4·0
(1·3–10·5)
5·9
(2·4–13·0)
5·9
(2·4–12·9)
4·0
(1·3–10·4)
3·0
(0·8–9·2)
3·0
(0·8–9·1)
5·9
(2·4–13·0)
6·0
(2·5–13·1)
Day 14
N 100 99 102 101 100 100 101 100
GMT 8·0
(6·8–9·5)
73·6
(55·1–98·1)
127·9
(96·8–168·9)
77·3
(60·0–99·5)
142·2
(107·9–187·4)
256·3
(199·0–330·2)
357·1
(277·3–459·9)
40·8
(31·9–52·4)
GMT ratio
1·1
(1·0–1·3)
11·5
(8·7–15·3)
18·7
(14·0–25·0)
11·0
(8·5–14·3)
20·8
(15·5–27·9)
39·4
(30·2–51·3)
48·3
(37·2–62·7)
4·8
(3·7–6·1)
Seroconversion (%)
3·0
(0·8–9·2)
70·7
(60·6–79·4)
84·3
(75·5–90·7)
73·3
(63·4–81·5)
86·0
(77·3–92·1)
95·0
(88·2–98·5)
95·0
(88·3–98·5)
50·0
(39·9–60·2)
Seroprotection (%)
9·0
(4·5–16·9)
72·7
(62·7–81·1)
86·3
(77·7–92·2)
77·2
(67·6–84·9)
90·0
(82·0–95·1)
96·0
(89·5–99·1)
97·0
(90·9–99·7)
56·0
(45·7–65·9)
Day 21
N 100 99 102 101 100 100 101 99
GMT 7·1
(6·3–8·1)
87·6
(65·4–117·3)
155·7
(117·0–207·1)
86·9
(66·3–113·8)
155·6
(116·5–207·8)
294·5
(221·9–390·7)
374·7
(289·9–484·3)
37·6
(29·1–48·6)
GMT ratio
1·0
(0·9–1·10
13·0
(10·2–18·0)
22·8
(16·8–30·9)
12·4
(9·5–16·3)
22·8
(16·8–31·0)
44·3
(33·0–59·5)
50·7
(39·2–65·5)
4·5
(3·5–5·8)
Seroconversion (%)
1·0
(0·0–6·3)
73·7
(63·8–82·0)
88·2
(80·0–93·7)
72·3
(62·3–80·6)
87·0
(78·4–92·9)
95·0
(88·2–98·5)
97·0
(90·7–99·7)
47·5
(37·4–57·8)
Seroprotection (%)
6·0
(2·5–13·1)
76·8
(67·0–84·6)
91·2
(83·5–95·9)
77·2
(67·6–84·9)
90·0
(82·0–95·1)
97·0
(90·8–99·7)
99·0
(93·8–100·0)
53·5
(43·3–63·6)
-
19
Table 6 Hemagglutination-inhibition antibody response after one dose in children and adolescents
Children (3–11 y) Adolescents (12–17 y)
Split-virion+Al Split-virion Split-virion+Al Split-virion
7·5 μg 15 μg 15 μg 30 μg 7·5 μg 15 μg 15 μg 30 μg
Before vaccination
N 102 100 100 102 100 100 101 102
GMT 5·3
(5·0–5·5)
5·4
(5·1–5·6)
5·2
(5·0–5·4)
5·6
(5·2–6·0)
8·6
(7·3–10·1)
8·6
(7·1–10·5)
8·9
(7·5–10·6)
9·1
(7·5–11·0)
Seroprotection (%)
0·0
(0·0–4·5)
0·0
(0·0–4·6)
0·0
(0·0–4·6)
1·0
(0·0–6·1)
11·0
(5·9–19·3)
9·0
(4·5–16·9)
11·9
(6·6–20·2)
8·8
(4·4–16·9)
Day 14
N / / / / 99 100 100 99
GMT / / / /
84·6
(66·6–107·6)
107·8
(84·0–138·3)
320·0
(248·0–412·9)
406·0
(319·3–516·3)
GMT ratio
/ / / /
9·9
(7·8–12·7)
12·5
(9·6–16·3)
35·8
(27·7–46·1)
44·5
(33·6–58·8)
Seroconversion (%)
/ / / /
76·8
(67·0–84·6)
78·0
(68·4–85·6)
98·0
(92·3–100·0)
97·0
(90·8–99·7)
Seroprotection (%)
/ / / /
84·8
(75·9–91·2)
85·0
(76·1–91·3)
99·0
(93·8–100·0)
99·0
(93·7–100·0)
Day 21
N 96 96 97 97 97 98 100 99
GMT 43·6
(35·4–53·8)
56·2
(46·4–67·7)
78·9
(63·4–98·1)
112·7
93·3–136·2
131·9
(101·5–171·4)
150·1
(115·8–194·6)
475·0
(359·7–627·3)
600·9
(458·3–787·9)
GMT ratio
8·3
(6·8–10·1)
10·5
(8·8–12·7)
15·1
(12·2–18·8)
20·1
(16·5–24·5)
15·3
(11·9–19·7)
17·3
(13·2–22·7)
53·1
(40·7–69·2)
65·8
(49·4–87·7)
Seroconversion (%)
63·5
(53·0–73·1)
81·3
(71·7–88·4)
81·4
(72·0–88·5)
94·8
(87·8–98·5)
87·6
(79·0–93·4)
82·7
(73·4–89·5)
98·0
(92·3–100·0)
98·0
(90·8–99·7)
Seroprotection (%)
63·5
(53·0–73·1)
81·3
(71·7–88·4)
81·4
(72·0–88·5)
95·9
(89·2–99·1)
92·8
(85·2–97·1)
87·8
(79·2–93·5)
98·0
(92·3–100·0)
100·0
(95·3–100·0)
-
20
Figure legend
Figure 1: Trial profile
Figure 2: Reverse cumulative distribution curve of hemagglutinatination-inhibition titers against
recombinant A/California/07/2009-A/PR/8/34 strain (X-179A) in elders (A), adults (B), adolescents (C)
and children (D) 21 days after the first dose.
Par
tici
pan
ts (
%)
-
21
Figure 1
703 donated samples and received
the 2nd dose on day 21
100 in placebo
99 in 5-μg whole-virion +Al
102 in 10-μg whole-virion +Al
101 in 7.5-μg split-virion +Al
100 in 15-μg split-virion +Al
100 in 15-μg split-virion
101 in 30-μg split-virion
100 donated
samples on day
21
394 donated samples and received
the 2nd dose on day 21
97 in 7.5-μg split-virion +Al
98 in 15-μg split-virion +Al
100 in 15-μg split-virion
99 in 30-μg split-virion
386 donated samples and received
the 2nd dose on day 21
96 in 7.5-μg split-virion +Al
96 in 15-μg split-virion +Al
97 in 15-μg split-virion
97 in 30-μg split-virion
Safety assess
Safety assess
Safety assess
Assessed for the immunogenicity on day 35 and
42
genicity
Assessed for the immuno-
genicity on day 35
Assessed for the immuno-
genicity on day 42
100 received placebo
101 received 5-μg whole-virion +Al
102 received 10-μg whole-virion +Al
101 received 7.5-μg split-virion +Al
100 received 15-μg split-virion +Al
101 received 15-μg split-virion
101 received 30-μg split-virion
100 received 10-μg
whole-virion +Al.
One was excluded
100 received 7.5-μg split-virion +Al
100 received 15-μg split-virion +Al
101 received 15-μg split-virion
102 received 30-μg split-virion
102 received 7.5-μg split-virion +Al
100 received 15-μg split-virion +Al
100 received 15-μg split-virion
102 received 30-μg split-virion
1614 eligible participants stratified by age
101 elders 403 adolescents randomly assigned 404 children randomly
assigned
706 adults randomly
assigned
Safety assess Safety assess Safety assess Safety assess
703 donated samples on day 14
100 in placebo
99 in 5-μg whole-virion +Al
102 in 10-μg whole-virion +Al
101 in 7.5-μg split-virion +Al
100 in 15-μg split-virion +Al
100 in 15-μg split-virion
101 in 30-μg split-virion
100 donated
samples on day
14
398 donated samples on day 14
99 in 7.5-μg split-virion +Al
100 in 15-μg split-virion +Al
100 in 15-μg split-virion
99 in 30-μg split-virion
-
22
El der s
0
1 0
20
30
40
50
60
70
80
90
1 00
5 1 0 20 40 80 1 60 320 640 1 280 2560
1 0μg W+Al
Adul t s
0
1 0
20
30
40
50
60
70
80
90
1 00
5 1 0 20 40 80 1 60 320 640 1 280 2560
5μg W+Al
1 0μg W+Al
7. 5μg S+Al
1 5μg S+Al
1 5μg S
30μg S
pl acebo
Adol escent s
0
1 0
20
30
40
50
60
70
80
90
1 00
5 1 0 20 40 80 1 60 320 640 1 280 2560
7. 5μg S+Al
1 5μg S+Al
1 5μg S
30μg S
Chi l dr en
0
1 0
20
30
40
50
60
70
80
90
1 00
5 1 0 20 40 80 1 60 320 640 1 280 2560
7. 5μg S+Al
1 5μg S+Al
1 5μg S
30μg S
Par
tici
pan
ts (
%)
Par
tici
pan
ts (
%)
Par
tici
pan
ts (
%)
Par
tici
pan
ts (
%)
Titer Titer
Titer Titer
A B
C D
Figure 2
-
23
-
1
The clinical trial of adjuvanted whole-virion, adjuvanted split-virion and non-adjuvanted
split-virion influenza A (H1N1)vaccines: a double-blind, randomized and controlled trial
Summary
A single center, double-blind, randomized and controlled clinical trial is to be conducted in heathy people aged
over 3-years to evaluate the safety and immunogenicity of adjuvanted whole-virion, adjuvanted split-virion
and non-adjuvanted split-virion influenza A (H1N1)vaccines. The vaccine investigated is producted in
embryonated hen's eggs using the H1N1 reference strain X-179A which is a reassortant between
A/California/07/2009 and A/PR/8/34 prepared by New York Medical College using classical reassortment
technology. Total 1600 volunteers aged over 3-years old will be enrolled, the eligible participants were
stratified by age: elders (≥61 years), adults (18–60 years), adolescent (12–17 years) and children (3–11 years).
The elders are assigned to receive one dose of openly-labelled, 10-μg, adjuvanted whole-virion vaccine. The
adults, adolescents and children are randomly assigned to receive two doses of blind-labelled vaccines or
placebo 21 days apart. The adults will receive 2 doses of 5 or 10 μg of adjuvanted, whole-virion vaccine, or 7·5
or 15 μg of adjuvanted, split-virion vaccine, or 15 or 30 μg of non-adjuvanted, split-virion vaccine, or placebo.
The adolescents and children will receive 2 doses of 7·5 or 15 μg of adjuvanted, split-virion vaccine, or 15 or
30 μg of non-adjuvanted, split-virion vaccine. Serum samples for the assessment of humoral immune response
are collected on day 0, 14, 21 and 35 for elders, day 0, 14, 21, 35 and 42 for adults and adolescents, and day 0,
21 and 42 for children, and then will be assayed by haemagglutination-inhibition (HI) methods against the
homologous X-179A strain. Local and systematic adverse reactions will be recorded during the study.
Backgroud
A novel swine-origin influenza A (H1N1) virus emerging in North America had caused a pandemic influenza
as declared by the World Health Organization (WHO) on June 11, 2009. As of July 3, 2009, more than 120
countries and regions worldwide reported around 90,000 cases, 382 of which were fatal. The rapid spread of
the virus and high morbidity caused by it has drawn wide attention from international community. So far
vaccine is considered as the most effective means to reduce the morbidity and mortality after infection,
* Protocol
-
2
especial for those who have underlying medical conditions.
Up to now, clinical evaluation of influenza A (H1N1) vaccine is ongoing in China, Australia, USA, Austria and
European Union. None of these trials has been completed. As registered in ClinicalTrials.gov, the vaccines to
be evaluated included whole-virion and split-virion vaccines, adjuvanted and non-adjuvanted vaccines,
egg-derived and cell-derived vaccines, all of which were monovalent vaccine. The dosage of the investigated
vaccines ranged from 3·75 μg to 30 μg, depending on the adjuvant and vaccine type. The study population
covered infants, children, adolescents, adults and elders. Two-dose vaccination schedule was adopted by all
these trials, most of which were 21-day interval. Based on the experience with H5N1 vaccine trials which
showed that two doses were necessary to induce satisfactory immune response in immunologically naïve
population, a double-blind, randomized and controlled trial was conducted in elders, adults, adolescents and
children to evaluate the immunogenicity and safety of influenza A (H1N1) vaccines manufactured by Sinovac
Biotech (Beijing, China)
Aims
The purpose is to evaluate immunogenicity and safety of influenza A (H1N1)vaccines in elders, adults,
adolescent and children and provide a basis to determine the best type and dose of vaccine and immunization
procedures.
General Informations
Principal Investigator
Jiang Wu, associate professor, Beijing Centers for Diseases Control and Prevention, Beijing, China.
Main Center
Beijing Centers for Diseases Control and Prevention
Contact Details
Jiang Wu
Tel and fax: 86-10-64407107
Email: [email protected]
Sponsors
Sinovac Biotech Co., Ltd, Beijing, China
mailto:[email protected]
-
3
Intending start date
July 2009
Intending finishing date
September 2009
Design
The trial is double blind, randomized and controlled study.
Inclusion Criteria
Healthy male or female aged 3 and older
Be able to show legal identity card for the sake of recruitment
Volunteers or their guardians are able to understand and sign the informed consent.
Exclusion Criteria
Cases, cured cases and close contact of influenza A (H1N1) virus
Women of pregnancy, lactation or about to be pregnant in 60 days
Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient
of vaccine, such as egg, egg protein, etc
Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema,
or abdominal pain
Autoimmune disease or immunodeficiency
Asthma that is unstable or required emergent care, hospitalization or intubation during the past two
years or that required the use of oral or intravenous corticosteroids
Diabetes mellitus (type I or II), with the exception of gestational diabetes
History of thyroidectomy or thyroid disease that required medication within the past 12 months
Serious angioedema episodes within the previous 3 years or requiring medication in the previous two
years
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder
requiring special precautions) or significant bruising or bleeding difficulties with IM injections or
blood draws
-
4
Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure
or malignancy that is likely to recur during the period of study
Seizure disorder other than:
1. Febrile seizures under the age of two years old
2. Seizures secondary to alcohol withdrawal more than 3 years ago, or
3. A singular seizure not requiring treatment within the last 3 years
Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
Guillain-Barre Syndrome
Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids
within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or
topical corticosteroids for an acute uncomplicated dermatitis)
History of any blood products or seasonal influenza vaccine administration within 3 months before the
dosing
Administration of any other investigational research agents within 30 days before the dosing
Administration of any live attenuated vaccine within 30 days before the dosing
Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment
with antigen injections, within 14 days before the dosing
Be receiving anti-TB prophylaxis or therapy currently
Axillary temperature > 37.0 centigrade at the time of dosing
Psychiatric condition that precludes compliance with the protocol:
1. Past or present psychoses
2. Past or present bipolar disorder requiring therapy that has not been well controlled on
medication for the past two years
3. Disorder requiring lithium
4. Suicidal ideation occurring within five years prior to enrollment
Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the
judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's
ability to give informed consent.
Intervention
The inactivated, aluminum-adjuvanted, whole-virion influenza (H1N1) vaccine is prepared on a pilot scale by
following procedures: the virus seed X-179A strain is grown in in embryonated hens’ eggs, harvested,
-
5
inactivated, purified and formulated with aluminum hydroxide. A 1.0 mL-dose contained 20 μg H1N1
haemagglutinin antigen, without preservative. Non-pathogenicity of the reassortant had been confirmed by the
National Institute for the Control of Pharmaceuticals and Biological Products (NIBSC) by use of various
animal model.
The aluminum-adjuvanted, split-virion influenza (H1N1) vaccine is prepared on a pilot scale by following
procedures: the virus seed X-179A strain is grown in in embryonated hens’ eggs, harvested, inactivated, splited,
purified and formulated with aluminum hydroxide. A 1.0 mL-dose contained 30 μg H1N1 haemagglutinin
antigen, without preservative. Non-pathogenicity of the reassortant had been confirmed by NIBSC by use of
various animal model.
The non-adjuvanted, split-virion influenza (H1N1) vaccine is prepared on a pilot scale by following procedures:
the virus seed X-179A strain is grown in in embryonated hens’ eggs, harvested, inactivated, splited and
purified. A 1.0 mL-dose contained 60 μg H1N1 haemagglutinin antigen, without preservative.
Non-pathogenicity of the reassortant had been confirmed by NIBSC by use of various animal model.
The reference strain was prepared by the UK National Institute for Biological Standards and Control (NIBSC),
and recommended as suitable for use as a prototype influenza vaccine strain by the European Union
Committee for Medicinal Products for Human Use (CHMP).
The study vaccine was produced by Sinovac Biotech Co., Ltd. and certified and released by NICPBP.
Treatment groups as follows:
Age Whole-virion
vaccine Split-virion vaccine Placebo Total
5μg
+Al
10μg
+Al
7.5μg
+Al
15μg 15μg
+Al
30μg
Elders 100 100
Adults 100 100
100 100 100 100
100 700
Adolescents 100 100 100 100 400
Children 100 100 100 100 400
Total 100 200 300 300 300 300 100 1600
The elders receive one dose and the adults, adolescent and children receive two doses apart 21 days. The
vaccines are administered intramuscularly into the deltoid muscle by nurse who will not participated in the
safety observation and immunogenic assessment.
-
6
Randomization
Those vaccines administered at 0,21 days regimen are subjected to randomization. A randomization list will be
generated at Sinovac Biotech by a statistician who is not involved in the rest of the trial. A randomized block
design is used, with a block size of a 1:1:1:1:1:1 ratio in adults, a 1:1:1:1 ratio in adolescents and children to
ensure that balance between vaccine types and dosages is maintained. Then the randomized vaccines of the
three formulations are blind labelled with a sequential number according to the randomization list. The blind
labelled vaccines are the same in appearance and the random code (A001-A700 for adults, N001-N400 for
adolescent and C001-C400 for children) is the only sign to identify the vaccines. The 10-μg, adjuvanted
whole-virion vaccine used for elders are openly labelled.
Allocation
The 700 adults, 400 adolescents and 400 children are randomly assigned (as seen in the table above) to receive
two doses of blind-labelled vaccine 21 days apart. The 100 elders are assigned to receive one doses of
openly-labelled 10-μg adjuvanted whole-virion vaccine.
Endpoints
The primary immunological endpoint is seroconversion rate of haemaggultination-inhibition (HI) antibody 14
days or 21 days after the first or the second dose. The vaccinees are defined as seroconversion who have a HI
titer before vaccination of less than 1:10 and a titer after vaccination of 1:40 or more, or a titer before
vaccination of 1:10 or more and at least a four fold increase after vaccination.
The secondary immunological endpoints include post-to-pre-vaccination geometric mean titer (GMT) ratio and
post-vaccination seroprotection rate (≥1:40, deemed to be the seroprotective threshold for seasonal influenza
vaccines).
Adverse events and reactions
Participants should be kept to observe adverse events for 30 minutes after receipt of every dose. Diary cards
will be used to record the presence and intensity of adverse events. For the next three days following
vaccination, any local adverse events (pain, erythema, swelling, induration, rash and itching) at the injection
site and systematic adverse events (allergic reactions, headache, dizziness, fatigue, angina, nausea, vomit,
inappetence, abdominal pain, diarrhea, myalgia, arthralgia, cough, fever) will be recorded by participants on
the first three diary cards. From the fourth day to the next visit, the adverse events will be recorded by
participants on the fourth dairy cards. The diameters of any erythema, swelling, induration and rash at the
-
7
injection site should be determined by investigators, and daily axillary temperature will be measured by
volunteers. The adverse events recorded by participants should be reviewed by members of the study staff. All
adverse events are graded by Adult Toxicity Table released by Division of Microbiology and Infectious
Diseases, USA.
The presence of solicited and unsolicited adverse events and any serious adverse events are described in terms
of the incidence, intensity and relation to vaccination. The incidence of adverse events is based on the most
severe response, and expressed in terms of the number and proportion of individuals who had adverse events in
each group.
Serious adverse event (SAE) is any untoward medical occurrence that at any dose:
- results in death
- is life-threatening
- requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability/incapacity
- or is a congenital anomaly/birth defect.
Investigators should report any SAE in 24 hours by telephone, fax or email to SFDA, sponsors, monitor, Data
Safety Monitoring Committee (DSMB) and ethical review committee of Beijing Centers for Diseases Control
and Prevention.
Immunological assay
Serum samples for the assessment of humoral immune response were collected on day 0, 14, 21 and 35 for
elders, day 0, 14, 21, 35 and 42 for adults and adolescents, and day 0, 21 and 42 for children. Serum sample
will be isolated under sterile conditions. Hemagglutination-inhibition (HI) antibody titers and
microneutralization antibody titers against the vaccine seed virus (X-179A) will be measured. The
immunogenic assays will be done under blinded conditions, i.e, the laboratory staffs do not know the treatment
groups and bleeding times. HI assays are to be done in accordance with established procedures with turkey
erythrocytes. Before titration, all serum samples will be treated with receptor-destroying enzyme (cholera
filtrate, Sigma) at 36℃ for 16 h to remove non-specific inhibitors of agglutination, then incubated at 56℃ to
inactivate the enzyme. Samples are tested in two-fold dilution starting with an initial dilution of 1 in 10. The
serum titers are expressed as the reciprocal of the highest dilution that shows complete inhibition of
-
8
hemagglutination. All samples will be assayed in duplicate and double-checked by at least two persons. For the
purpose of calculation, HI titres below 1:10 are assigned a value of 1:5.
Statistical analysis
Safety and immunogenicity were the co-primary objectives. The incidence of adverse events was based on the
most severe response, expressed in terms of the number and proportion of individuals who had adverse events.
The safety data were summarized in the full-analysis set.
The immunologic endpoints were based on HI licensure criteria set out by the European Union Committee for
Medicinal Products for Human Use (CHMP) including geometric mean titre (GMT), post-to-pre-vaccination
GMT ratio, seroconversion rate and seroprotection rate. Seroconversion rate is defined as the percentage of
vaccinees who have a titre before vaccination of less than 1:10 and a titre after vaccination of 1:40 or more, or
a titre before vaccination of 1:10 or more and at least a fourfold increase after vaccination. HI titre≥1:40 is
considered as seroprotection in seasonal influenza vaccine, which is temporally adopted for influenza A (H1N1)
vaccine in this study. The antibody titres were transformed into logarithmic scale for the calculation of GMT.
The titre distributions were described with reverse cumulative distribution curves. The immunogenic data were
summarized in the per-protocol set.
The results of immunogenicity and safety are summarized with point estimates and two-sided 95%CI. The
antibody titers are transformed into logarithmic scale for the calculation of GMT and 95%CI. Statistical
analysis is done by intension to treatment (ITT). Immunogenic data are summarized in the per-protocol
population. Pearson’s chi-square test or Fisher’s exact test are used to compare groups when relevant.
Spearman’s correlation coefficient is used to assess the correlation between HI titer and neutralization titer. The
significance level was 0·05 (two-sided).
Ethical issues
The trial was registered with the ClinicalTrials.gov number NCT00956111 and approved by the Chinese
regulatory authority State Food and Drug Administration (SFDA) and Chinese CDC. All relevant documents
were approved by the ethical review committee of Beijing Centers for Disease Control and Prevention. All
participants provided their written informed consent.